Teligent Targets Smaller Customers As It Seeks Sustainable Margins
You may also be interested in...
US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.
US topicals, ophthalmics and injectables generics player Teligent has asked an investment bank to help it explore selling off non-core assets. The New Jersey-based firm wants funds to help capitalize on its newly built injectables facility.
US niche generics specialist Teligent is at a loss to explain why its share price has tumbled in recent times as it ramps up production at an expanded injectables facility.